A Double-blind, Randomized, Parallel Group, Phase IV Study to Investigate the Effects of DAPAgliflozin on CARDiac Substrate Uptake, Myocardial Efficiency and Myocardial Contractile Work in Type 2 Diabetes Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DAPACARD
- Sponsors AstraZeneca
- 07 Feb 2019 Planned End Date changed from 1 Apr 2019 to 2 Apr 2019.
- 07 Feb 2019 Planned primary completion date changed from 1 Apr 2019 to 2 Apr 2019.
- 07 Feb 2019 Status changed from recruiting to active, no longer recruiting.